Home > Protocol Summaries: Compounds > GW493838 Protocol Summaries: GW493838 GSKStudy ID Phase Title Status A1A20004 Phase 2 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Tolerability of a 14 Day Treatment Course of GW493838 50mg Compared to Placebo in Subjects with Peripheral Neuropathic Pain Completed